SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories shines on launching Favipiravir for COVID-19 treatment

06 Aug 2020 Evaluate

Alkem Laboratories is currently trading at Rs. 2955.00, up by 113.00 points or 3.98% from its previous closing of Rs. 2842.00 on the BSE.

The scrip opened at Rs. 2900.00 and has touched a high and low of Rs. 2972.60 and Rs. 2900.00 respectively. So far 4295 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2975.65 on 04-Aug-2020 and a 52 week low of Rs. 1,682.10 on 07-Aug-2019.

Last one week high and low of the scrip stood at Rs. 2975.65 and Rs. 2538.20 respectively. The current market cap of the company is Rs. 33980.37 crore.

The promoters holding in the company stood at 62.43%, while Institutions and Non-Institutions held 15.52% and 21.80% respectively.

Alkem Laboratories has launched Favipiravir under the brand name ‘Alfluenza’ in India for the management of mild to moderate cases of COVID-19. Favipiravir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

Alkem Laboratories Share Price

5583.70 16.00 (0.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×